• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

COMPASS Pathways Plc - American Depository Shares (NQ:CMPS)

11.35 -0.22 (-1.90%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 31, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about COMPASS Pathways Plc - American Depository Shares

< Previous 1 2 3 4 5 6 7 8 9
...
32 33 Next >
News headline image
Why Compass Pathways Stock Rocketed 40% Today ↗
April 20, 2026
Compass Pathways may be the first to benefit from an accelerated approval process. 
Via The Motley Fool
Topics Government
News headline image
Trump Just Fast-Tracked Psychedelic Treatments: 3 Under-the-Radar Stocks That Could Be About to Soar ↗
April 20, 2026
Trump is easing approval for psychedelic treatments for mental disorders. 
Via The Motley Fool
Topics Government
These stocks are gapping in today's session ↗
April 20, 2026
Via Chartmill
Top movers in Monday's pre-market session ↗
April 20, 2026
Via Chartmill
CMPS Stock Climbs 5% In Premarket After FDA Clears PTSD Trial Path ↗
January 07, 2026
Via Stocktwits
News headline image
Compass Pathways to Participate in Needham Virtual Psychedelics Forum on April 27, 2026
April 20, 2026
From Compass Pathfinder Limited
Via Business Wire
News headline image
Compass Pathways Commends White House Executive Order to Accelerate Research and Access for Psychedelic Treatments
April 18, 2026
From Compass Pathfinder Limited
Via Business Wire
News headline image
The Psychedelic Revolution in Mental Healthcare ↗
April 17, 2026
Founders of the Integrative Psychiatry Institute, Dr. Will Van Derveer and Keith Kurlander, discuss their new book, Psychedelic Therapy: A Revolutionary Approach to Restoring Mental Health and... 
Via The Motley Fool
News headline image
Compass Pathways Announces U.S Grant Program for the Creation of Post-Approval COMP360 Provider Training
April 14, 2026
From Compass Pathfinder Limited
Via Business Wire
News headline image
Compass Pathways to Attend Needham Virtual Healthcare Conference on April 14, 2026
April 08, 2026
From Compass Pathfinder Limited
Via Business Wire
News headline image
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 07, 2026
From Compass Pathfinder Limited
Via Business Wire
News headline image
The 15-Minute Breakthrough: A Deep Dive into GH Research (GHRS) and the Future of Rapid-Acting Psychedelics
March 26, 2026
Today’s Date: March 26, 2026 Introduction As the global mental health crisis reaches unprecedented levels, the pharmaceutical industry has been forced to look beyond traditional SSRIs toward more... 
Via Finterra
Topics Cannabis Initial Public Offering Intellectual Property
News headline image
Compass Pathways Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Highlights
March 24, 2026
From Compass Pathfinder Limited
Via Business Wire
News headline image
Compass Pathways to Present at Stifel 2026 Virtual CNS Forum on March 18, 2026
March 12, 2026
From Compass Pathfinder Limited
Via Business Wire
News headline image
Compass Pathways Announces Exercise of $200 Million in Outstanding Warrants
February 26, 2026
From Compass Pathfinder Limited
Via Business Wire
News headline image
Next-Generation Psychiatric Therapies Target Massive $40B+ Market Opportunity
February 24, 2026
EQNX::TICKER_START (NASDAQ:HELP),(CBOE:HELP),(NYSE:TAK),(NASDAQ:CMPS),(NYSE:PFE),(NYSE:BMY) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
Compass Pathways to attend TD Cowen 46th Annual Healthcare Conference in Boston, MA from March 2-4, 2026
February 24, 2026
From Compass Pathfinder Limited
Via Business Wire
News headline image
Magic Mushrooms, Hard Cash: Compass Pathways’ Trial Win, Fast Raise ↗
February 20, 2026
Via MarketBeat
News headline image
Nasdaq, S&P 500 Futures Edge Higher, Trump Speech In Focus: Why WMT, META, IBRX, MSFT, EBAY Are On Traders' Radar Today ↗
February 19, 2026
Data from Stocktwits indicated retail sentiment towards SPY and QQQ cooled to neutral. 
Via Stocktwits
Topics ETFs Economy Government
News headline image
Compass Pathways Announces Pricing of $150 Million Public Offering
February 18, 2026
From Compass Pathfinder Limited
Via Business Wire
News headline image
CMPS Stock Slumps Premarket As $150M Offering Cuts Into Psychedelic Trial Buzz ↗
February 18, 2026
The company CMPS is planning to seek FDA guidance on a rolling review and target a New Drug Application submission in the fourth quarter. 
Via Stocktwits
News headline image
Compass Pathways Launches Proposed $150.0 Million Public Offering
February 17, 2026
From Compass Pathfinder Limited
Via Business Wire
Let's have a look at the top gainers and losers in the middle of the day of today's session. ↗
February 17, 2026
Via Chartmill
News headline image
Why Did Compass Pathways Stock Rocket Higher Today? ↗
February 17, 2026
Compass Pathways hopes to submit an NDA in Q4 leading up to potential approval. 
Via The Motley Fool
Tuesday's session: gap up and gap down stocks ↗
February 17, 2026
Via Chartmill
Tuesday's pre-market session: top gainers and losers ↗
February 17, 2026
Via Chartmill
News headline image
Compass Pathways Successfully Achieves Primary Endpoint in Second Phase 3 Trial Evaluating COMP360 Psilocybin for Treatment-Resistant Depression
February 17, 2026
From Compass Pathfinder Limited
Via Business Wire
News headline image
CMPS Stock Rises 23% Pre-Market As Compass Achieves Primary Endpoint In Phase 3 Treatment-Resistant Depression Trial ↗
February 17, 2026
COMPASS Pathways is currently conducting clinical trials of COMP360, a proprietary synthetic formulation of psilocybin, designed for treatment-resistant depression. 
Via Stocktwits
News headline image
CMPS Stock Jumps 22% Pre-Market As Compass Sets Timeline For New Phase 3 Depression Trial Results ↗
February 17, 2026
The company is currently conducting clinical trials of COMP360, a proprietary synthetic formulation of psilocybin, designed for treatment-resistant depression. 
Via Stocktwits
News headline image
Compass Pathways to Announce New Clinical Data from Two Ongoing Phase 3 Trials
February 16, 2026
From Compass Pathfinder Limited
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
32 33 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap